Please assess the completion status of the following clinical trial:

Trial Title: High-Dose Melphalan With or Without Radiolabeled Monoclonal Antibody in Treating Patients With Multiple Myeloma Undergoing an Autologous Stem Cell Transplant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically proven multiple myeloma (MM)~* Scheduled to undergo autologous hematopoietic stem cell transplantation (HSCT) as consolidation treatment for MM~  * Must have sufficient CD34-positive stem cells (≥ 4 x 10\^6 cells per kg body weight) in cryo-storage for two autologous HSCTs~* In partial remission (PR) after prior chemotherapy but before priming therapy for stem cell mobilization~  * Patients in complete remission (CR) after prior chemotherapy are not eligible~* Bone marrow cellularity ≥ 20%~PATIENT CHARACTERISTICS:~* WHO performance status 0-1~* Life expectancy ≥ 24 weeks~* Hemoglobin ≥ 9.0 g/dL~* Neutrophils ≥ 1,500/mm³~* Platelets ≥ 50,000/mm³~* Serum bilirubin ≤ 1.5 times upper limit of normal (ULN)~* ALT and/or AST ≤ 2.5 times ULN~* Creatinine clearance ≥ 50 mL/min~* Not pregnant or nursing~* Negative pregnancy test~* Fertile female patients must use effective contraception for 4 weeks prior to, during, and for 6 months after completion of study treatment~* Fertile male patients must use effective contraception during and for 6 months after completion of study treatment~* Able to cooperate with study treatment and follow up~* Human anti-mouse antibody (HAMA) negative~* No active uncontrolled infection~* No high-risk non-malignant systemic disease~* No other condition, that in the investigator's opinion, would make the patient an unsuitable candidate for the study~* No known HIV or hepatitis B or C seropositivity~* No history of allergy, including an allergy to rodents or rodent proteins~* No history of eczema or asthma~* No history of New York Heart Association (NYHA) class III or IV cardiac disease~* No congestive heart failure~PRIOR CONCURRENT THERAPY:~* Recovered from prior therapy~  * Alopecia or certain grade 1 toxicities allowed~* More than 4 weeks since prior radiotherapy (except for localized pain control), endocrine therapy, or immunotherapy~* More than 4 weeks since prior and no other concurrent chemotherapy for the underlying hematological condition, except for the following:~  * Cyclophosphamide as priming for stem cell harvest~ * Thalidomide~* More than 3 weeks since prior major thoracic and/or abdominal surgery and recovered~* No prior high-dose therapy and autologous HSCT~* Concurrent radiotherapy allowed for the control of bone pain~  * The irradiated lesions are not used for response evaluation~* No other concurrent anti-cancer therapy or investigational drugs during transplantation conditioning

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- radio-labelled anti-CD66 monoclonal antibody (Type: EXPERIMENTAL): Up to 4mg radio-labelled anti-CD66 monoclonal antibody. Plus standard treatment
- No IMP - standard treatment (Type: ACTIVE_COMPARATOR): No IMP - standard treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues